Cogent Biosciences

We’re excited to share that the FDA has accepted our NDA for bezuclastinib in patients with AdvSM. It's our third NDA acceptance this year! We’re deeply grateful to the patients, families, & investigators and the entire Cogent team. bit.ly/4ipkjpv

Today we reported our second quarter 2026 financial results and recent business highlights. Read the full press release here: bit.ly/4cvhT4G

The #GISTCommunity has always had a powerful voice. At #LifeFest2026 in Nashville those voices were captured on the GIST community guitar thru messages of strength, hope, & encouragement. TY to everyone who shared a message & to @liferaftgroup for bringing the community together.

We’re thrilled to announce that we've submitted our third New Drug Application (NDA) to the U.S. FDA with bezuclastinib; this one for #AdvSM! This submission is a testament to the tireless work of our team and our dedication to patients. Read our PR here: bit.ly/4bgnqeQ

Last week we welcomed Patient Advocacy Leaders from the rare disease & cancer communities to our first Elevation Summit in Boulder. Participants shared valuable expertise & perspectives that will help inform future action & deepen our collective impact. TY to all who contributed!

We’re in Stockholm for #EHA2026 presenting updated data from our APEX trial in AdvSM as well as pathobiology data in AdvSM & preclinical data from our JAK2 V617F program. Read more here: bit.ly/43x57xT and find our posters & presentations here: bit.ly/4dGfBkx

Today we shared detailed clinical data and updates from our #GIST program being presented at #ASCO26. Read the release: bit.ly/4uES49o and find the presentation here: bit.ly/4dGfBkx

Our team is heading to the #ASCO26 where we’re presenting detailed clinical data in Gastrointestinal Stromal Tumors #GIST. We hope to see you there!

We’re thrilled to share that the FDA has accepted our 2nd NDA this year! Our combo of bezuclastinib + sunitinib for patients w/#GIST received Priority Review! We're deeply grateful to the patients, families, investigators & entire Cogent team. Read more: bit.ly/4va65vK

Join us for a fireside chat at the @Jefferies Global Healthcare conference in New York on June 3 at 11:05am ET. Register and listen to the webcast here. bit.ly/4wSfRnN #JefferiesHealthcare

We’re excited to present pivotal data from our APEX trial in #AdvSM & preclinical data from our emerging JAK2 V617F program at #EHA2026. We look forward to seeing you in Stockholm & connecting w/the hematology community! Find presentation details here bit.ly/4wqTG83.

Today we reported our first quarter 2026 financial results, highlighting continued momentum with bezuclastinib and our pipeline. Read more here: bit.ly/49c71am

We’re pleased to share that the Phase 3 PEAK trial has been selected for an oral presentation at #ASCO26. We’ll present data from our trial of bezuclastinib in combo w/sunitinib in patients w/GIST who have received prior treatment w/imatinib. Read more: bit.ly/3QzSaA4

At #AACR26 we’re presenting new preclinical data on our pan-KRAS inhibitor showcasing its selectivity profile which could lead to reduction in skin tox & from our brain penetrant ErbB2 inhibitor w/evidence of synergistic activity in combo w/HER2 ADCs. PR: bit.ly/4enZFnC

Today we announced we've submitted our second New Drug Application to the U.S. FDA with bezuclastinib; this one for #GIST! The NDA was submitted under the FDA’s RTOR program. It’s another important milestone for patients & for Cogent! Read our PR: bit.ly/48nRd3R

We're excited to share that the FDA has accepted our NDA for bezuclastinib in patients with NonAdvanced SM. We’re thankful to the patients, families, investigators & the entire Cogent team who made this significant achievement possible. Read more: bit.ly/4cLC2Vi

Cogent is driven by our commitment 2 advancing therapies 4 those living w/#SystemicMastocytosis & #GIST. On #RareDiseaseDay , we wore stripes 2 raise awareness, show our support 4 the #SM & #GIST communities, & reflect on the people who inspire our work each day. #ShowYourStripes

We’re excited to be at the #AAAAI26 ! Today we’re presenting data from 6 bezuclastinib posters. Read the release bit.ly/4u27RiQ and find the posters here bit.ly/40x1vue. If you missed us at the poster sessions come see us in booth 917 in the Exhibit Hall!

Our team is heading to the American Academy of Allergy, Asthma & Immunology Annual Meeting where we’re presenting six SUMMIT posters in NonAdvanced SM. The Exhibit Hall opens Feb 27 and our posters are Feb 28 at 9:45am ET. We hope to see you there! #NonAdvSM #AAAAI26

Today we shared our 4QFY 2025 financial results and recent business highlights. We’re proud of our progress and look forward to what’s ahead. Read the full press release here: bit.ly/4kIQvDm